| Q34436061 | 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism |
| Q38845403 | 80-year-old man with massive leg swelling |
| Q42109168 | A 52-year-old-male patient with metastatic non-small-cell lung cancer and recurrent venous thromboembolism in unusual sites despite anticoagulation |
| Q35849625 | A case of Trousseau syndrome caused by pulmonary adenocarcinoma that was controlled for one year and 10 months with thrombosis treatment using an EGFR tyrosine kinase inhibitor and chemotherapy |
| Q38002155 | A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism |
| Q33431673 | A critical balance: managing coagulation in patients with glioma |
| Q46704451 | A descriptive evaluation of warfarin use in patients receiving hospice or palliative care services |
| Q37729777 | A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective anticoagulation length with low molecular weight heparin in the treatment of cancer associated thrombosis (ALICAT): study pr |
| Q36883723 | A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. |
| Q37293267 | A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment |
| Q33419224 | A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center |
| Q38656360 | ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism. |
| Q57168017 | Ability of the Khorana score to predict recurrent thromboembolism in cancer patients with ischemic stroke |
| Q51846266 | Acquired Thrombophilia. |
| Q55040734 | Acute Pulmonary Embolism in Emergency Department Patients Despite Therapeutic Anticoagulation. |
| Q92088563 | Acute arterial thrombosis during adjuvant Adriamycin-cyclophosphamide chemotherapy in a patient with early breast cancer: A case report |
| Q35948275 | Acute deep vein thrombosis cases in the real world |
| Q37788951 | Acute pulmonary embolism. Part 2: treatment |
| Q42144837 | Acute pulmonary embolus in the course of cancer |
| Q41995517 | Advanced testicular cancer in a society of racial and socio-economic health disparity |
| Q44669273 | Advances in brain metastases presented at the American Society of Clinical Oncology 2016 Annual Meeting: Part I. |
| Q40049073 | Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model |
| Q37772221 | Ambulatory management of pulmonary embolism: a pragmatic evaluation |
| Q36002461 | An automated database case definition for serious bleeding related to oral anticoagulant use. |
| Q53493824 | An in-vitro study on corn-shaped balloon-enhanced thrombolysis. |
| Q98183389 | An overview of thrombotic complications of old and new anticancer drugs |
| Q37588677 | Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism |
| Q44125195 | Anaplastic astrocytoma |
| Q39027741 | Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer |
| Q35593973 | Anti-thrombotic therapy in cancer patients |
| Q26776112 | Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art |
| Q98183405 | Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia |
| Q64067376 | Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis |
| Q37831345 | Anticoagulant use in cancer patients |
| Q38062284 | Anticoagulant use in real time |
| Q55326290 | Anticoagulantes orais diretos no tratamento do tromboembolismo venoso em pacientes com câncer. |
| Q26825228 | Anticoagulants in cancer |
| Q33370259 | Anticoagulants in pregnancy |
| Q38805398 | Anticoagulants versus cancer. |
| Q43660477 | Anticoagulating the subsegmental pulmonary embolism in cancer patients: a survey amongst different medical specialties |
| Q47448340 | Anticoagulation for noncardiac indications in neurologic patients: comparative use of non-vitamin k oral anticoagulants, low-molecular-weight heparins, and warfarin |
| Q38096441 | Anticoagulation for prevention and treatment of cancer-related venous thromboembolism. |
| Q91659077 | Anticoagulation for the Treatment of Cancer-Associated Thrombosis: A Systematic Review and Network Meta-Analysis of Randomized Trials |
| Q24243286 | Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer |
| Q24194904 | Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer |
| Q24236620 | Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer |
| Q57689134 | Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer |
| Q38610888 | Anticoagulation for the treatment of venous thromboembolism in patients with brain metastases: a meta-analysis and systematic review. |
| Q55506528 | Anticoagulation in the Elderly. |
| Q37844474 | Anticoagulation in the management of venous thromboembolism in the cancer patient |
| Q37794614 | Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents |
| Q48157907 | Anticoagulation prescribing patterns in patients with cancer |
| Q49788980 | Anticoagulation strategies in patients with deep vein thrombosis and pulmonary artery embolisms |
| Q96292008 | Anticoagulation treatment of cancer patients with deep or superficial leg vein thrombosis - a retrospective observational study of German statutory health insurance claims data (the CERTIFICAT initiative) |
| Q24633053 | Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q55364590 | Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options. |
| Q55286559 | Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms. |
| Q34362901 | Antithrombotic therapy in cardiac embolism |
| Q33416407 | Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization |
| Q42289797 | Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report |
| Q53160538 | Approach to venous thromboembolism in the cancer patient. |
| Q37278718 | Are all low molecular weight heparins equivalent in the management of venous thromboembolism? |
| Q34635182 | Arterial and venous thrombosis in cancer patients |
| Q33438981 | Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer Patients with Acute Myocardial Infarction |
| Q26796430 | Assessing the risk of recurrent venous thromboembolism--a practical approach |
| Q36829227 | Assessing, preventing, and treating venous thromboembolism: evidence-based approaches |
| Q47186286 | Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants |
| Q40070964 | Barriers to the diagnosis and treatment of venous thromboembolism in advanced cancer patients: a qualitative study |
| Q47322291 | Barriers to the long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis |
| Q37197069 | Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism |
| Q44908247 | Best supportive care of pancreatic carcinoma |
| Q34171922 | Bevacizumab in Combination with folfiri Chemotherapy in Patients with Metastatic Colorectal Cancer: An Assessment of Safety and Efficacy in the Province of Newfoundland and Labrador |
| Q42426059 | Biased estimation of thrombosis rates in cancer studies using the method of Kaplan and Meier |
| Q36030515 | Biological and clinical aspects of anticancer effects of antithrombotics. |
| Q59328822 | Biomarkers and potential pathogenesis of colorectal cancer-related ischemic stroke |
| Q91979024 | Biomarkers of Cancer-Associated Thromboembolism |
| Q35880101 | Biosimilars of low-molecular-weight heparin products: fostering competition or reducing 'biodiversity'? |
| Q33377454 | Bleeding and thrombosis in acute leukemia: what does the future of therapy look like? |
| Q33415521 | Bleeding complications during anticoagulant treatment in patients with cancer |
| Q34627819 | Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study |
| Q91086780 | Breaking the exclusiveness of LMWH for treating cancer-associated VTE |
| Q55510457 | Bullous hemorrhagic dermatosis is an under-recognized side effect of full dose low-molecular weight heparin: a case report and review of the literature. |
| Q34771524 | CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients |
| Q56515861 | COSIMO - patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study |
| Q33422300 | Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment |
| Q36079937 | Cancer Cell-Derived Extracellular Vesicles Are Associated with Coagulopathy Causing Ischemic Stroke via Tissue Factor-Independent Way: The OASIS-CANCER Study |
| Q33439089 | Cancer and Venous Thromboembolic Disease: A Review |
| Q36391554 | Cancer and coagulation |
| Q37057951 | Cancer and thrombosis: an increasingly important association |
| Q37533816 | Cancer and thrombosis: implications of published guidelines for clinical practice. |
| Q36617737 | Cancer and thrombosis: managing the risks and approaches to thromboprophylaxis |
| Q33358854 | Cancer and thrombosis: mechanisms and treatment |
| Q41846813 | Cancer and thrombosis: recent advances |
| Q33763866 | Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management |
| Q83004214 | Cancer and venous thromboembolism |
| Q34422539 | Cancer and venous thromboembolism. |
| Q36956320 | Cancer and venous thromboembolism: prevention, treatment and survival |
| Q37393386 | Cancer, clots and consensus: new understanding of an old problem. |
| Q57475170 | Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment |
| Q93092246 | Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines-A Multidisciplinary (SEMI-SEOM-SETH) Expert Consensus |
| Q51496815 | Cancer-Associated Thrombosis: Regulatory Mechanisms and Emerging Directions. |
| Q38748038 | Cancer-Associated Venous Thromboembolism |
| Q47110130 | Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins |
| Q37702182 | Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study |
| Q33389006 | Cancer-associated thrombosis. |
| Q93257690 | Cancer-associated thrombosis: Role of direct oral anticoagulants |
| Q34655217 | Cancer-associated thrombosis: an overview |
| Q36410631 | Cancer-associated thrombosis: prevention and treatment |
| Q37998004 | Cancer-related venous thromboembolic disease: current management and areas of uncertainty |
| Q64117212 | Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association |
| Q45073137 | Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. |
| Q92446802 | Case-Based Review: newly diagnosed glioblastoma |
| Q53618446 | Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: guidance from the SSC of the ISTH. |
| Q38121179 | Catheter-related thrombosis in cancer patients |
| Q57653940 | Catheter-related thrombosis: A practical approach |
| Q27314885 | Cerebral ischemic events in patients with pancreatic cancer: A retrospective cohort study of 17 patients and a literature review |
| Q36474763 | Changing paradigms in the management of venous thromboembolism |
| Q87041629 | Cholangiocarcinoma: another masquerader in the making? |
| Q33372266 | Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach |
| Q95729132 | Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous Thromboembolism |
| Q36205646 | Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis |
| Q37309626 | Clinical and histopathological effects of presurgical treatment with sunitinib for renal cell carcinoma with inferior vena cava tumor thrombus at a single institution. |
| Q33420469 | Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations |
| Q34553530 | Clinical guide SEOM on venous thromboembolism in cancer patients |
| Q38205701 | Clinical models and biochemical predictors of VTE in lung cancer |
| Q57216129 | Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry |
| Q90480321 | Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism |
| Q37848581 | Clinical outcomes of a pharmacist-managed anticoagulation service for breast cancer patients |
| Q48322684 | Clinical presentation and ischemic zone on MRI in cancer patients with acute ischemic stroke |
| Q35368813 | Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes |
| Q34416283 | Clues to occult cancer in patients with ischemic stroke |
| Q38070918 | Coagulation and cancer: biological and clinical aspects |
| Q37204966 | Coagulation, anticoagulation and pancreatic carcinoma. |
| Q47845649 | Colorectal cancer and thrombosis. |
| Q54705508 | Comment on "tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients". |
| Q54728791 | Commentary on "microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation". |
| Q39788611 | Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin |
| Q96134578 | Comparative analysis of enoxaparin versus rivaroxaban in the treatment of cancer associated venous thromboembolism: experience from a tertiary care cancer centre |
| Q36160668 | Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival |
| Q48506942 | Comparative outcomes of thrombocytopenic acute leukemic patients with venous thromboembolism at a Comprehensive Cancer Center. |
| Q38061872 | Comparing clinicians' use of an anticoagulation management service and usual care in ambulatory oncology. |
| Q38996813 | Comparison of Enoxaparin and Warfarin for Secondary Prevention of Cancer-Associated Stroke |
| Q91592270 | Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers |
| Q36557766 | Complex Perioperative Decision-Making: Liver Resection in a Patient with Extensive Superior Vena Cava/Right Atrial Thrombus and Superior Vena Cava Syndrome |
| Q92276384 | Complications and management of coagulation disorders in leukemia patients |
| Q40409105 | Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice. |
| Q33436975 | Controversies in the management of cancer-associated thrombosis |
| Q33396240 | Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer |
| Q41464532 | Cost-Effectiveness Analysis of Treatment Acute Deep Vein Thrombosis in Clinic of Vascular Surgery Sarajevo. |
| Q38640906 | Critical Review and Update on the Treatment of Acute and Chronic Pulmonary Embolism |
| Q34626836 | Cryptogenic subtype predicts reduced survival among cancer patients with ischemic stroke |
| Q90194029 | Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions |
| Q61804277 | Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants |
| Q38675822 | Current challenges and future prospects in oral anticoagulant therapy |
| Q36265574 | Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient |
| Q90480224 | Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis |
| Q57461614 | D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis |
| Q44605363 | Dalteparin Compared with an Oral Anticoagulant for Thromboprophylaxis in Patients with Cancer |
| Q47574970 | Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria |
| Q37587205 | Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis |
| Q83951221 | Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis |
| Q35559025 | Declining Long-term Risk of Adverse Events after First-time Community-presenting Venous Thromboembolism: The Population-based Worcester VTE Study (1999 to 2009). |
| Q33635174 | Deep Vein Thrombosis of the Upper Extremity |
| Q81584045 | Deep vein thrombosis |
| Q30249169 | Deep vein thrombosis and pulmonary embolism |
| Q36085302 | Deep vein thrombosis in cancer: the scale of the problem and approaches to management |
| Q34144439 | Deep vein thrombosis: a clinical review |
| Q30369732 | Deep vein thrombosis: current status and nanotechnology advances. |
| Q34785968 | Developing a complex intervention for the outpatient management of incidentally diagnosed pulmonary embolism in cancer patients. |
| Q26795642 | Developments in the management and treatment of pulmonary embolism |
| Q45847579 | Diagnosis and anticoagulant treatment |
| Q34346557 | Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? A qualitative study |
| Q24673847 | Diagnosis and treatment of deep-vein thrombosis |
| Q37611378 | Diagnosis and treatment of deep-vein thrombosis and approach to venous thromboembolism in obstetrics and gynecology |
| Q30315531 | Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thro |
| Q35637534 | Diagnostic yield of echocardiography in cancer patients with ischemic stroke. |
| Q39907289 | Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung |
| Q42718620 | Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism |
| Q61805375 | Direct Oral Anticoagulant Drugs: On the Treatment of Cancer-Related Venous Thromboembolism and their Potential Anti-Neoplastic Effect |
| Q96690257 | Direct Oral Anticoagulants In Patients With Hematologic Malignancies |
| Q92991920 | Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019? |
| Q104072357 | Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient) |
| Q53273545 | Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. |
| Q103796318 | Direct oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement |
| Q47284901 | Direct oral anticoagulants and cancer: no swansong yet for the low-molecular-weight heparins |
| Q57172950 | Direct oral anticoagulants for the treatment of venous thromboembolism in patients with active malignancy: a systematic review and meta-analysis |
| Q92648688 | Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients |
| Q92486918 | Direct oral anticoagulants in gastrointestinal malignancies: is the convenience worth the risk? |
| Q33875888 | Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism |
| Q47340283 | Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism? |
| Q90348186 | Direct versus conventional anticoagulants for treatment of cancer associated thrombosis: a pooled and interaction analysis between observational studies and randomized clinical trials |
| Q49574798 | Direkte orale Antikoagulanzien bei Krebspatienten: Sind wir so weit? |
| Q35845738 | Discovery of an intrinsic tenase complex inhibitor: Pure nonasaccharide from fucosylated glycosaminoglycan |
| Q37188135 | Doxorubicin-induced vascular toxicity--targeting potential pathways may reduce procoagulant activity |
| Q38851927 | Drug Treatment of Venous Thromboembolism in the Elderly. |
| Q53925224 | Drug therapy in anticoagulation: which drug for which patient? |
| Q99628207 | Drug-Drug Interactions of 257 Antineoplastic and Supportive Care Agents With 7 Anticoagulants: A Comprehensive Review of Interactions and Mechanisms |
| Q34284224 | Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term |
| Q33249813 | EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force |
| Q39582489 | Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment |
| Q35445037 | Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada |
| Q93377019 | Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide |
| Q89287401 | Edoxaban for the treatment of cancer associated venous thromboembolism as an alternative to low-molecular-weight-heparin |
| Q39540721 | Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. |
| Q54960660 | Effect of Statins on Survival Following Stroke in Patients With Cancer. |
| Q45896126 | Effect of long-term LMWH on post-thrombotic syndrome in patients with iliac/noniliac venous thrombosis: a subanalysis from the home-LITE study |
| Q24187370 | Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in patients with unprovoked VTE |
| Q24202706 | Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in patients with unprovoked VTE |
| Q38612417 | Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE. |
| Q58578339 | Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE |
| Q48111369 | Effectiveness and Safety of Anticoagulants for the Treatment of Venous Thromboembolism in Patients With Cancer. |
| Q49888849 | Effectiveness and Safety of LMWH Treatment in Patients With Cancer Diagnosed With Non-High-Risk Venous Thromboembolism: Turkish Observational Study (TREBECA). |
| Q36416675 | Effectiveness of warfarin among patients with cancer |
| Q38741507 | Effects of Long-Term Low-Molecular-Weight Heparin on Fractures and Bone Density in Non-Pregnant Adults: A Systematic Review With Meta-Analysis. |
| Q58129801 | Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial |
| Q101216950 | Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials |
| Q36066023 | Emerging strategies for treatment of venous thromboembolism |
| Q26864863 | Endovascular Interventions for Acute and Chronic Lower Extremity Deep Venous Disease: State of the Art |
| Q33439387 | Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study |
| Q37935403 | Enoxaparin once daily vs. twice daily dosing for the treatment of venous thromboembolism in cancer patients: a literature summary |
| Q35544736 | Epidemiology and management of venous thromboembolism in patients with cancer |
| Q41903910 | Essay for the CIHR/CMAJ award: the role of low-molecular-weight heparin therapy venous thromboembolism |
| Q33392669 | Established Venous Thromboembolism Therapies: Heparin, Low Molecular Weight Heparins, and Vitamin K Antagonists, with a Discussion of Heparin-Induced Thrombocytopenia |
| Q53656553 | Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality. |
| Q37924503 | Evaluation and management of chronic pulmonary thromboembolic disease |
| Q38627234 | Evaluation of Direct-Acting Oral Anticoagulant Use in Patients With Cancer |
| Q39424848 | Evaluation of anticoagulation selection for acute venous thromboembolism. |
| Q47211898 | Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study |
| Q64115894 | Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill |
| Q49647319 | Evidence Gaps in the Era of Non-Vitamin K Oral Anticoagulants. |
| Q33763946 | Evidence-based guidance on venous thromboembolism in patients with solid tumours |
| Q34047821 | Evolving use of new oral anticoagulants for treatment of venous thromboembolism |
| Q46917778 | Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism |
| Q92490153 | Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study |
| Q33508936 | FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer |
| Q47663774 | Factors Associated with Anticoagulation Delay Following New-Onset Atrial Fibrillation. |
| Q38938521 | Factors influencing adherence to clinical guidelines in the management of cancer-associated thrombosis. |
| Q36195033 | Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism |
| Q38184560 | Fatal paraneoplastic embolisms in both circulations in a patient with poorly differentiated neuroendocrine tumour |
| Q33362095 | Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study |
| Q41985454 | Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients |
| Q42400148 | Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients |
| Q81167533 | Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients |
| Q36836684 | Giant right ventricular outflow tract thrombus in hereditary spherocytosis: a case report |
| Q28076077 | Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment |
| Q28079081 | Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism |
| Q28066527 | Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism |
| Q28069131 | Guidance for the prevention and treatment of cancer-associated venous thromboembolism |
| Q36471056 | Guidance for the treatment and prevention of obstetric-associated venous thromboembolism |
| Q45877193 | Guideline on aspects of cancer-related venous thrombosis |
| Q37868637 | Guidelines for supportive care in multiple myeloma 2011. |
| Q40519867 | Guidelines for the diagnosis, treatment, and follow-up of pulmonary embolism |
| Q34484090 | Guidelines on oral anticoagulation (warfarin): third edition--2005 update |
| Q28240666 | Guidelines on oral anticoagulation with warfarin - fourth edition |
| Q35525678 | Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study |
| Q37784315 | Heparin as an inhibitor of cancer progression. |
| Q26821781 | Heparin in malignant glioma: review of preclinical studies and clinical results |
| Q38214957 | Heparins and cancer survival: where do we stand? |
| Q37500092 | Heparins attenuate cancer metastasis: are selectins the link? |
| Q39243093 | Heparins modulate the IFN-γ-induced production of chemokines in human breast cancer cells |
| Q37708829 | Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis |
| Q38481302 | High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives |
| Q96772641 | Hormones and Thrombosis: Risk Across the Reproductive Years and Beyond |
| Q88683204 | How I diagnose and treat venous thromboembolism in sickle cell disease |
| Q92771647 | How I treat cancer-associated thrombosis |
| Q37854717 | How to improve the implementation of guidelines on cancer-related thrombosis |
| Q37903951 | How to prevent, treat, and overcome current clinical challenges of VTE. |
| Q37640879 | Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: The OASIS-CANCER Study |
| Q79673958 | Idiopathic and recurrent thromboembolic phenomena in cancer patients |
| Q33153412 | Imminent pulmonary embolism: a fatal mobile right atrial thrombus. |
| Q38065298 | Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis. |
| Q57788269 | Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment |
| Q33561203 | Impact of venous thromboembolism and anticoagulation on cancer and cancer survival |
| Q46863568 | Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways |
| Q52313102 | Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma. |
| Q33391777 | Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors |
| Q48661559 | Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study |
| Q52686996 | Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma. |
| Q38805405 | Incidental venous thromboembolic events in cancer patients: what we know in 2016. |
| Q102214589 | Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin |
| Q35948264 | Inferior vena cava filters for primary prophylaxis: when are they indicated? |
| Q34462703 | Inferior vena cava filters: current best practices |
| Q38081938 | Initial and long-term treatment of deep venous thrombosis: recent clinical trials and their impact on patient management. |
| Q39359007 | Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs? |
| Q46626799 | Initial management of deep venous thrombosis in the outpatient setting |
| Q53077850 | Initiation of exemestane in two warfarin-treated patients leading to elevation and variability of INR. |
| Q36960618 | Ins and outs of inferior vena cava filters in patients with venous thromboembolism: the experience at Monash Medical Centre and review of the published reports |
| Q37738699 | Intensity of warfarin coagulation in the antiphospholipid syndrome |
| Q38979052 | International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer |
| Q37588675 | International recommendations for the prevention and treatment of venous thromboembolism associated with cancer |
| Q35994289 | Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. |
| Q83663365 | Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial |
| Q36764001 | Investigational treatments of venous thromboembolism |
| Q36413874 | Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes. |
| Q41554922 | Is it useful to also image the asymptomatic leg in patients with suspected deep vein thrombosis? |
| Q46514222 | Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study |
| Q37903682 | Ischemic stroke and cancer: stroke severely impacts cancer patients, while cancer increases the number of strokes |
| Q52597188 | Ischemic stroke in cancer patients: A review of an underappreciated pathology. |
| Q47688786 | Ischemic stroke in patients with cancer: is it different from usual strokes? |
| Q45070965 | Key questions to be answered |
| Q38566744 | L-asparaginase and venous thromboembolism in acute lymphocytic leukemia |
| Q38805402 | LMWH in cancer patients with renal impairment - better than warfarin? |
| Q33375535 | Latest medical treatment strategies for venous thromboembolism |
| Q50048427 | Lesson of the month 2: Pulmonary embolism in a patient on rivaroxaban and concurrent carbamazepine. |
| Q37740294 | Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients |
| Q41292245 | Levels of activated platelet-derived microvesicles in patients with soft tissue sarcoma correlate with an increased risk of venous thromboembolism |
| Q47201370 | Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism. |
| Q35664286 | Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices? |
| Q46770289 | Long-term administration of a low-molecular-weight heparin contributed to successful treatment in a patient with primary mediastinal large B-cell lymphoma and venous thromboembolism |
| Q88775693 | Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial |
| Q39145374 | Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant |
| Q37243904 | Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer? |
| Q44197966 | Low molecular weight heparin administration in cancer patients with hypercoagulability-related complications and carrying brain metastases: a case series study. |
| Q38749053 | Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms |
| Q36295906 | Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism |
| Q37943009 | Low molecular weight heparins in the treatment of lung cancer |
| Q35975553 | Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months |
| Q36265588 | Low-molecular-weight heparin and survival in patients with malignant disease |
| Q47331892 | Low-molecular-weight heparin for the treatment of acute venous thromboembolism in patients with active cancer. |
| Q36022983 | Low-molecular-weight heparin for the treatment of venous thromboembolism in the elderly |
| Q34688195 | Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival |
| Q38376242 | Low-molecular-weight heparins and cancer: focus on antitumoral effect |
| Q33380411 | Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review |
| Q38600392 | Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness. |
| Q37490581 | Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings |
| Q64108218 | Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study |
| Q33417504 | Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study |
| Q26749273 | Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis |
| Q57825250 | Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review |
| Q59612892 | Management of atrial fibrillation in patients taking targeted cancer therapies |
| Q40806195 | Management of bleeding complications in patients with cancer on DOACs |
| Q53348197 | Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH. |
| Q50082184 | Management of cancer-associated venous thromboembolism - a case-based practical approach |
| Q36013024 | Management of cancer-associated venous thrombosis |
| Q38468723 | Management of isolated calf vein thrombosis in cancer patients |
| Q36524815 | Management of massive and nonmassive pulmonary embolism |
| Q33622659 | Management of occlusion and thrombosis associated with long-term indwelling central venous catheters |
| Q44304204 | Management of pulmonary embolism: state of the art treatment and emerging research |
| Q33431420 | Management of recurrent venous thromboembolism in cancer patients |
| Q46408588 | Management of refractory venous thrombosis associated with malignancy using a supra-therapeutic enoxaparin regimen |
| Q37119201 | Management of stroke in cancer |
| Q36018537 | Management of thrombosis in cancer: primary prevention and secondary prophylaxis |
| Q38126391 | Management of thrombotic complications in acute lymphoblastic leukemia |
| Q30417015 | Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. |
| Q37621554 | Management of venous thromboembolism and the potential to impact overall survival in patients with cancer |
| Q37489073 | Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. |
| Q39794332 | Management of venous thromboembolism in cancer patients: the economic burden of hospitalizations |
| Q37176707 | Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. |
| Q36248507 | Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants? |
| Q37903957 | Management of venous thromboembolism in patients with cancer |
| Q36812767 | Management of venous thromboembolism in patients with cancer: role of dalteparin |
| Q36590609 | Management of venous thromboembolism in the elderly |
| Q37133050 | Management of venous thromboembolism in the palliative care setting |
| Q79686128 | Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians |
| Q28071443 | Management of venous thromboembolism: an update |
| Q38542829 | Managing Disease and Therapy-Related Complications in Patients with Central Nervous System Tumors |
| Q37810063 | Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond |
| Q57254147 | Managing medical complications in patients with brain tumors |
| Q36395279 | Managing oral anticoagulation requires expert experience and clinical evidence |
| Q90480677 | Managing thrombosis in cancer patients |
| Q46361565 | Marantic endocarditis presenting with multifocal neurological symptoms |
| Q26992262 | Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review |
| Q36216552 | Mechanisms of disease: the impact of antithrombotic therapy in cancer patients |
| Q26992174 | Medical management of brain tumors and the sequelae of treatment |
| Q79811506 | Medical management of patients with brain tumors |
| Q38514328 | Medical management of tumor lysis syndrome, postprocedural pain, and venous thromboembolism following interventional radiology procedures |
| Q35614816 | Medical reversal: why we must raise the bar before adopting new technologies |
| Q34419638 | Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism |
| Q47797800 | Need for inferior vena cava filters in cancer patients: a surrogate marker for poor outcome |
| Q40283816 | Neoadjuvant chemotherapy followed by radiotherapy and concurrent hyperthermia in patients with advanced-stage cervical cancer: a retrospective study |
| Q55283799 | Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Patients With Cancer: A Systematic Review and Trade-Off Analysis From 9 Randomized Controlled Trials. |
| Q37810672 | Neurological complications of systemic cancer |
| Q52675244 | New Trends in Anticoagulation Therapy. |
| Q42907043 | New and Emerging Anticoagulant Therapies for Venous Thromboembolism |
| Q43775570 | New and old anticoagulants in cancer |
| Q38831847 | New anticoagulants for the treatment of venous thromboembolism |
| Q37744931 | New challenges for a second-generation low-molecular-weight heparin: focus on bemiparin. |
| Q36270022 | New development in anticoagulant and antithrombotic therapy: are we on the right track? |
| Q37307380 | New insights into cancer-associated thrombosis |
| Q37519054 | New oral anticoagulants and the cancer patient. |
| Q27001528 | New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities |
| Q46832922 | New strategies in the secondary prevention of relapsing venous thromboembolism |
| Q64238367 | Non-vitamin K Antagonist Oral Anticoagulants (NOAC) as an Alternative Treatment Option in Tumor-Related Venous Thromboembolism |
| Q35494098 | Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes |
| Q38964210 | Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease |
| Q87713618 | Nonbacterial thrombotic endocarditis presenting as intracerebral hemorrhage |
| Q37086868 | Nonbacterial thrombotic endocarditis: A rare manifestation of gynecologic cancer |
| Q89002085 | Novel Anticoagulant Treatment for Pulmonary Embolism with Direct Oral Anticoagulants Phase 3 Trials and Clinical Practice |
| Q50100461 | Once-Daily Versus Twice-Daily Enoxaparin for the Treatment of Acute Venous Thromboembolism in Cancer Patients |
| Q90376945 | Operative and peri-operative considerations in the management of brain metastasis |
| Q89513805 | Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials |
| Q34781477 | Optimal duration of anticoagulation after venous thromboembolism |
| Q35210139 | Optimal duration of anticoagulation in patients with venous thromboembolism. |
| Q46202395 | Optimizing transition of care through the facilitation of a pharmacist-managed deep vein thrombosis treatment program |
| Q64962466 | Oral Anticoagulation. |
| Q47907077 | Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience |
| Q38108205 | Oral anticoagulants in the management of venous thromboembolism |
| Q46195264 | Oral anticoagulat treatment in venous thromboembolic disease |
| Q53337476 | Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. |
| Q53083500 | Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. |
| Q37790089 | Outpatient Management of Patients following Pulmonary Embolism |
| Q35863905 | Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. |
| Q36951531 | Outpatient-based primary and secondary thromboprophylaxis with low-molecular-weight heparin |
| Q36794824 | Pain management, supportive and palliative care in patients with renal cell carcinoma |
| Q39014043 | Palliative Care for Pancreatic and Periampullary Cancer |
| Q39433192 | Palliative care and advance care planning for pancreas and other cancers. |
| Q34140498 | Pancreatic adenocarcinoma |
| Q26775634 | Pancreatic cancer and thromboembolic disease, 150 years after Trousseau |
| Q35937439 | Pancreatic cancer and thromboembolic disease. |
| Q92413795 | Pancreatic cancer-A disease in need: Optimizing and integrating supportive care |
| Q24244310 | Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation |
| Q36734996 | Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review |
| Q36775341 | Pathogenesis, clinical and laboratory aspects of thrombosis in cancer |
| Q38084608 | Pathophysiology and management of thrombosis in cancer: 150 years of progress |
| Q47270528 | Patient Adherence and Experience with Extended Use of Prophylactic Low-Molecular-Weight Heparin Following Pancreas and Liver Resection |
| Q48015781 | Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes |
| Q33425797 | Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey |
| Q35752584 | Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q44872469 | Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. |
| Q38777127 | Pharmacodynamics, pharmacokinetics and clinical efficacy of apixaban in the treatment of thrombosis |
| Q36510063 | Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children |
| Q33685447 | Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange. |
| Q39029202 | Pharmacological management of pulmonary embolism |
| Q47651905 | Physicians' decision about long-term thromboprophylaxis in cancer outpatients: CAT AXIS, a case vignette study on clinical practice in France. |
| Q93000221 | Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus |
| Q35048404 | Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation |
| Q92556952 | Platelets and Immune Responses During Thromboinflammation |
| Q40360297 | Poor short-term outcome in patients with ischaemic stroke and active cancer |
| Q30278059 | Portal vein thrombosis: When to treat and how? |
| Q57056338 | Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer |
| Q38088606 | Postintervention duration of anticoagulation in venous surgery |
| Q89977542 | Potential Mechanisms of Cancer-Related Hypercoagulability |
| Q37740303 | Potential of new anticoagulants in patients with cancer |
| Q37832976 | Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure |
| Q36885516 | Practical problems and resource implications with the use of warfarin for venous thromboembolism in patients with cancer |
| Q39306435 | Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib. |
| Q38214962 | Predicting recurrent venous thromboembolism in cancer: is it possible? |
| Q26865059 | Predicting the risk of venous thromboembolism recurrence |
| Q34855983 | Predictive score for estimating cancer after venous thromboembolism: a cohort study |
| Q93092131 | Predictors of Early Mortality in Cancer-Associated Thrombosis: Analysis of the RIETE Database |
| Q38805443 | Predictors of recurrent venous thromboembolism and bleeding on anticoagulation. |
| Q48840907 | Predictors of survival for patients with cancer after cryptogenic stroke |
| Q33781172 | Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study |
| Q34721483 | Preparation and characterization of self-assembled nanoparticles based on low-molecular-weight heparin and stearylamine conjugates for controlled delivery of docetaxel |
| Q38646426 | Presence of Concomitant Systemic Cancer is Not Associated with Worse Functional Long-Term Outcome in Patients with Intracerebral Hemorrhage. |
| Q38686333 | Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy |
| Q37681486 | Prevention and treatment of thromboembolic events in medical patients and new anticoagulants |
| Q84140441 | Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines |
| Q36595944 | Prevention and treatment of venous thromboembolism in patients with cancer |
| Q41877145 | Prevention and treatment of venous thromboembolism in patients with cancer |
| Q48203843 | Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians |
| Q37265242 | Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines |
| Q44905222 | Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry |
| Q37038414 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma |
| Q89448175 | Prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants: A systematic review and meta-analysis |
| Q89599157 | Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand? |
| Q36062161 | Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists |
| Q26753853 | Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review |
| Q92978766 | Prognosis and risk factors in older patients with lung cancer and pulmonary embolism: a propensity score matching analysis |
| Q50014624 | Prognostic assessment for patients with cancer and incidental pulmonary embolism |
| Q41002912 | Prognostic significance of the absolute monocyte counts in lung cancer patients with venous thromboembolism |
| Q48393708 | Prolonged postoperative venous thrombo-embolism prophylaxis is cost-effective in advanced ovarian cancer patients |
| Q37310820 | Prophylactic and therapeutic anticoagulation for thrombosis: major issues in oncology |
| Q33413690 | Prophylaxis and treatment of venous thromboembolism in cancer patients. Clinical value of low-molecular-weight heparins |
| Q36705104 | Prophylaxis and treatment of venous thromboembolism in patients with cancer. |
| Q36705123 | Prophylaxis and treatment of venous thromboembolism in patients with cancer: an update |
| Q48015257 | Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline |
| Q87051993 | Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer |
| Q79954098 | Pulmonary embolism |
| Q86875175 | Pulmonary embolism and stroke as the initial manifestation of advanced metastatic pancreatic adenocarcinoma |
| Q30476617 | Pulmonary embolism in hospital practice |
| Q37587189 | Pulmonary embolism in non-brain tumor patients after surgery-a retrospective study in China |
| Q35011270 | Pulmonary embolism in pregnancy. |
| Q37264096 | Pulmonary embolism incidence is increasing with use of spiral computed tomography |
| Q46800985 | Pulmonary embolism: current treatment options |
| Q28074248 | Pulmonary embolism: the diagnosis, risk-stratification, treatment and disposition of emergency department patients |
| Q37770632 | Pulmonary thromboembolic disease. Clinical management of acute and chronic disease. |
| Q55252651 | Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC). |
| Q33389637 | Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). |
| Q61797453 | Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges |
| Q37099148 | Recent advances in cardiorespiratory medicine: management of pulmonary embolism and prevention of venous thromboembolism, recent treatment strategies in childhood asthma, and dermatological adverse reactions to cardiovascular drugs |
| Q41930344 | Recent advances in the management of venous thromboembolism |
| Q91812150 | Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges |
| Q38569212 | Recent developments in the diagnosis and treatment of pulmonary embolism. |
| Q37903926 | Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. |
| Q37942593 | Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum period |
| Q41705428 | Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin |
| Q50128324 | Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin |
| Q42171355 | Recurrent deep vein thrombosis despite warfarin therapy in a patient with Crohn's disease |
| Q33965434 | Recurrent thromboembolic events after ischemic stroke in patients with cancer |
| Q37213987 | Respiratory review of 2013: pulmonary thromboembolism |
| Q36556204 | Retrievable Inferior Vena Cava Filters in Patients with Cancer: Complications and Retrieval Success Rate |
| Q38676172 | Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study |
| Q92200830 | Retrospective evaluation of the efficacy and safety of rivaroxaban in patients with cancer-associated venous thromboembolism: A single-center study |
| Q38017371 | Risk and management of thrombosis in multiple myeloma |
| Q34153343 | Risk assessment for recurrent venous thrombosis |
| Q53149578 | Risk factors and clinical outcome of unsuspected pulmonary embolism in cancer patients: a case-control study. |
| Q40494174 | Risk factors for venous thromboembolic events in cancer patients |
| Q40079432 | Risk of Arterial Thromboembolism in Patients With Cancer. |
| Q91600794 | Risk of Cancer-Associated Thrombosis and Bleeding in Veterans With Malignancy Who Are Receiving Direct Oral Anticoagulants |
| Q38972501 | Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: a systematic review and meta-analysis. |
| Q64279924 | Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study |
| Q89947425 | Rivaroxaban Versus Low-molecular-weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer |
| Q40183661 | Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer |
| Q36997736 | Rivaroxaban for the treatment of pulmonary embolism |
| Q91788777 | Rivaroxaban treatment of cancer-associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience |
| Q92392581 | Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer |
| Q58802183 | Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis |
| Q38093435 | Role of the new oral anticoagulants in treatment of venous throboembolism |
| Q84706716 | SEOM guidelines on thrombosis in cancer patients |
| Q33393653 | Saddle pulmonary embolism in a cancer patient with thrombocytopenia: a treatment dilemma |
| Q37653934 | Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. |
| Q39333385 | Safe-dose thrombolysis plus rivaroxaban for moderate and severe pulmonary embolism: drip, drug, and discharge. |
| Q38523012 | Safety of anticoagulant treatment in cancer patients |
| Q33429840 | Safety of anticoagulation in thrombocytopenic patients with hematologic malignancies: A case series |
| Q49123780 | Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients |
| Q52729386 | Safety of long-term anticoagulation in patients with brain metastases. |
| Q33365781 | Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature |
| Q44988252 | Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period |
| Q81139832 | Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest |
| Q90732621 | Severe Fatal Systemic Embolism Due to Non-Bacterial Thrombotic Endocarditis as the Initial Manifestation of Gastric Adenocarcinoma: Case Report |
| Q38620799 | Sialic acids in cancer biology and immunity. |
| Q47193041 | Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer |
| Q38894516 | Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies |
| Q92431492 | Specific Biomarkers of Prostate Cancer-Associated Ischemic Stroke: A Case-Control Study |
| Q55386134 | Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018. |
| Q39971719 | Stability of plasma anti-Xa activity in low-molecular-weight heparin monitoring |
| Q90182016 | Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies |
| Q86037979 | Stroke and Cancer- A Complicated Relationship |
| Q37517289 | Successful thrombolytic therapy for acute kidney injury secondary to thrombosis of suprarenal inferior vena cava filter |
| Q41771347 | Superior Vena Cava Syndrome due to Thrombosis: A Rare Paraneoplastic Presentation of Bronchogenic Carcinoma |
| Q30444752 | Supportive management of patients with brain tumors |
| Q51352154 | Supratherapeutic INR resulting from the initiation of warfarin in a patient receiving axitinib. |
| Q40224140 | Surgical management of nonbacterial thrombotic endocarditis in malignancy |
| Q36036279 | Survival analysis in hematologic malignancies: recommendations for clinicians |
| Q41996717 | Synchronous Ovarian and Endometrial Endometrioid Adenocarcinoma Presenting with Nonbacterial Thrombotic Endocarditis and Pulmonary Thromboembolism: Adenocarcinoma with Thrombotic Events |
| Q50049162 | Synthesis of Fucosylated Chondroitin Sulfate Glycoclusters: A Robust Route to New Anticoagulant Agents |
| Q99579057 | Systemic thromboembolism from a misdiagnosed non-bacterial thrombotic endocarditis in a patient with lung cancer: A case report |
| Q48316812 | Testicular vein thrombosis: Incidence of recurrent venous thromboembolism and survival. |
| Q84140485 | The "common soil hypothesis": evidence from population studies? |
| Q56529734 | The Efficacy and Safety of Rivaroxaban and Dalteparin in the Treatment of Cancer Associated Venous Thrombosis |
| Q38805447 | The International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) at the Peak of Adolescence - 15 Years and Counting |
| Q90890058 | The Management of Venous Thromboembolic Disease: New Trends in Anticoagulant Therapy |
| Q84140444 | The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients |
| Q52719266 | The Platelet Lifeline to Cancer: Challenges and Opportunities. |
| Q58776758 | The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis |
| Q36888938 | The Role of Inferior Vena Cava Filters in Cancer Patients |
| Q51165894 | The Role of New Oral Anticoagulants (NOACs) in Cancer Patients. |
| Q47681124 | The Role of Tinzaparin in Oncology. |
| Q33435329 | The Treatment of Venous Thromboembolism in Patients with Cancer |
| Q36936771 | The antineoplastic effect of low-molecular-weight heparins - a literature review |
| Q34450928 | The association of active cancer with venous thromboembolism location: a population-based study |
| Q92081522 | The biomarkers and potential pathogenesis of lung cancer related cerebral hemorrhage |
| Q36995852 | The challenges of managing cancer related venous thromboembolism in the palliative care setting |
| Q75320388 | The clinical thrombosis center and clinical thrombologist: a new US health systems paradigm for the management of venous thromboembolic disease |
| Q92722756 | The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice |
| Q38005356 | The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients |
| Q26852293 | The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials |
| Q28296482 | The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials |
| Q35095964 | The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer |
| Q37006628 | The effects of low molecular weight heparins on venous thromboembolism and survival in patients with cancer |
| Q36021780 | The heparins and cancer: review of clinical trials and biological properties |
| Q37959385 | The impact of quality and duration of enoxaparin therapy on recurrent venous thrombosis in children |
| Q37802536 | The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer |
| Q90655131 | The intertwined fates of inflammation and coagulation in glioma |
| Q33363464 | The management of thromboembolic disease in patients with central nervous system malignancies |
| Q37029835 | The management of venous thromboembolism in cancer patients |
| Q39699871 | The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells |
| Q37868149 | The perioperative management of an inferior vena caval tumor thrombus in patients with renal cell carcinoma |
| Q36051099 | The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis |
| Q33698360 | The potential benefits of low-molecular-weight heparins in cancer patients |
| Q37316352 | The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants |
| Q93357580 | The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation |
| Q36615454 | The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area |
| Q47393865 | The role of direct oral anticoagulants in cancer-related venous thromboembolism: a perspective beyond the guidelines |
| Q36179286 | The role of thrombolysis in the clinical management of deep vein thrombosis |
| Q37740315 | The roles of anticoagulants in patients with cancer |
| Q36000885 | The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients |
| Q33402515 | The therapeutic management of bleeding and thrombotic disorders complicating CNS malignancies |
| Q38560196 | The treatment of cancer associated thrombosis: does one size fit all? Who should get LMWH/warfarin/DOACs? |
| Q48948053 | The treatment of cancer-associated venous thromboembolism in the era of the novel oral anticoagulants |
| Q37240578 | The treatment of deep vein thrombosis in the pelvis and leg |
| Q33376620 | The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients. |
| Q47959893 | Therapeutic Anticoagulation in Patients with Primary Brain Tumors or Secondary Brain Metastasis |
| Q44822583 | Therapeutic approaches to acute pulmonary embolism |
| Q83093566 | Therapy Insight: venous-catheter-related thrombosis in cancer patients |
| Q44701973 | Therapy and secondary prevention of venous thromboembolism with vitamin K antagonists |
| Q38083556 | Thromboembolic disease in cancer patients |
| Q42407190 | Thromboembolic disease in patients with high-grade glioma |
| Q37000726 | Thromboembolic events in pregnancy: pharmacological prophylaxis and treatment |
| Q36588644 | Thromboembolism in cancer patients: pathogenesis and treatment |
| Q37076622 | Thromboembolism in gastrointestinal cancers. |
| Q89071126 | Thromboprophylaxis in Head and Neck Microvascular Reconstruction |
| Q37023306 | Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer |
| Q91979003 | Thrombosis and Hemostasis in Cancer. Scope of the Problem and Overview |
| Q56339353 | Thrombosis and cancer |
| Q49332638 | Thrombosis in cancer patients: etiology, incidence, and management |
| Q98183403 | Thrombosis in hematological malignancies: mechanisms and implications |
| Q38364922 | Thrombosis in leukemia: incidence, causes, and practical management |
| Q28219961 | Thrombosis in multiple myeloma |
| Q33437325 | Thrombosis in the setting of cancer. |
| Q38117735 | Thrombosis in women: what are the knowledge gaps in 2013? |
| Q33723390 | Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients |
| Q36470049 | Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. |
| Q57787454 | Transabdominal two-cavity approach for radical nephrectomy combined with inferior vena cava thrombectomy for malignant thrombus caused by renal cell carcinoma: a case series |
| Q89090609 | Treating clots in cancer: moving closer to an answer? |
| Q38647343 | Treating patients with cancer and acute venous thromboembolism |
| Q33400564 | Treating venous thromboembolism in patients with cancer |
| Q59126194 | Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus |
| Q61804235 | Treatment and Prevention of Cancer-Associated Thrombosis in Frail Patients: Tailored Management |
| Q35865373 | Treatment and secondary prevention of venous thromboembolism in cancer |
| Q44188629 | Treatment for patients with cancer |
| Q90172812 | Treatment of Cancer-Associated Thrombosis: Beyond HOKUSAI |
| Q36956364 | Treatment of DVT: how long is enough and how do you predict recurrence |
| Q48846277 | Treatment of Medical Complications in Patients with Brain Tumors |
| Q35621012 | Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches |
| Q91979035 | Treatment of Venous Thromboembolism in Cancer. Historical Perspective and Evolving Role of the Direct Oral Anticoagulants |
| Q51196995 | Treatment of borderline resectable pancreatic cancer. |
| Q92662520 | Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants |
| Q42333953 | Treatment of central venous catheter-associated deep venous thrombosis in cancer patients with rivaroxaban |
| Q36063745 | Treatment of deep vein thrombosis: what factors determine appropriate treatment? |
| Q33401715 | Treatment of established thrombotic events in patients with cancer |
| Q37176044 | Treatment of plasma cell dyscrasias with lenalidomide |
| Q37773994 | Treatment of thromboembolism in cancer patients |
| Q33387992 | Treatment of venous thromboembolism |
| Q37393202 | Treatment of venous thromboembolism during pregnancy |
| Q41133589 | Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study |
| Q38554324 | Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. |
| Q98183383 | Treatment of venous thromboembolism in patients with cancer: from clinical trials to real life |
| Q37541850 | Treatment of venous thromboembolism: guidelines translated for the clinician |
| Q36484329 | Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency |
| Q53617803 | Trousseau's syndrome related to adenocarcinoma of the colon and cholangiocarcinoma. |
| Q26778607 | Trousseau's syndrome: cancer-associated thrombosis |
| Q37419797 | Unanswered questions in venous thromboembolism |
| Q95424345 | Unprovoked venous thromboembolism: assess for cancer |
| Q46130988 | Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. |
| Q38805434 | Update of thrombosis in multiple myeloma |
| Q38849824 | Update on Anticoagulation: What the Interventional Radiologist Needs to Know |
| Q91785608 | Update on Management of Portal Vein Thrombosis and the Role of Novel Anticoagulants |
| Q36286443 | Update on the diagnosis and management of pulmonary embolism. |
| Q52805260 | Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. |
| Q37199934 | Use of anticoagulants in elderly patients: practical recommendations |
| Q45065598 | Use of direct oral anticoagulants in patients on immunomodulatory agents. |
| Q53161523 | Use of thromboprophylaxis in palliative care patients: a survey among experts in palliative care, oncology, intensive care, and anticoagulation. |
| Q24632982 | VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q46497825 | Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis |
| Q39446006 | Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score |
| Q55539736 | Venous Thromboembolism Prophylaxis. |
| Q58692354 | Venous Thromboembolism in Cancer Patients Undergoing Major Abdominal Surgery: Prevention and Management |
| Q26741697 | Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants |
| Q38381351 | Venous Thromboembolism in Cancer: Frequently Asked Questions When Guidelines are Inconclusive |
| Q38944457 | Venous Thromboembolism in Patients Diagnosed With Lung Cancer |
| Q57045108 | Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations |
| Q33408419 | Venous access catheter-related thrombosis in patients with cancer |
| Q33374683 | Venous gangrene and cancer: a cool look at a burning issue |
| Q24631121 | Venous thromboembolic disease |
| Q36636027 | Venous thromboembolic disease and cancer |
| Q84140439 | Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management |
| Q36427605 | Venous thromboembolism and anticoagulant therapy in pregnancy |
| Q33685299 | Venous thromboembolism and bleeding in a community setting. The Worcester Venous Thromboembolism Study |
| Q54727911 | Venous thromboembolism and cancer: current issues and treatment updates. |
| Q38805438 | Venous thromboembolism and occult cancer: impact on clinical practice |
| Q37103079 | Venous thromboembolism and pancreatic cancer: incidence, pathogenesis and clinical implications. |
| Q43016566 | Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management |
| Q91831456 | Venous thromboembolism in cancer patients: Still looking for answers |
| Q26852015 | Venous thromboembolism in cancer patients: an underestimated major health problem |
| Q38751462 | Venous thromboembolism in cancer patients: risk assessment, prevention and management |
| Q53991767 | Venous thromboembolism in hospitalized patients with active cancer. |
| Q85739457 | Venous thromboembolism in malignancy |
| Q98183385 | Venous thromboembolism in palliative care patients: what do we know? |
| Q37867284 | Venous thromboembolism in patients with cancer: an overview for pharmacists using a case-based approach |
| Q54975217 | Venous thromboembolism in patients with cancer: design and rationale of a multicentre, prospective registry (Cancer-VTE Registry). |
| Q36535503 | Venous thromboembolism in patients with diffuse large B-cell lymphoma |
| Q33434346 | Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia |
| Q37812380 | Venous thromboembolism in pregnancy |
| Q36916924 | Venous thromboembolism prevention in cancer patients: the search for common antecedents |
| Q33561213 | Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action |
| Q36427613 | Venous thromboembolism risk and management in women with cancer and thrombophilia |
| Q37404403 | Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis |
| Q38932419 | Venous thromboembolism treatment outcomes in cancer patients and effect of third-party payers on anticoagulant choice |
| Q26825608 | Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation |
| Q37702728 | Venous thromboembolism: a clinical review |
| Q92711119 | Venous thromboembolism: current management |
| Q38053898 | Venous thromboembolism: diagnosis and current anticoagulation strategies for deep vein thrombosis and pulmonary embolism |
| Q89217812 | Venous thrombosis |
| Q36265592 | Venous thrombotic events in cancer: the bottom line |
| Q47202217 | Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review. |
| Q37130019 | Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio? |
| Q38189131 | What are the pharmacotherapy options for treating venous thromboembolism in cancer patients? |
| Q27009514 | What is the Best Treatment for a Cancer Patient with Thrombosis? |
| Q36097571 | What is the optimum strategy for thromboembolic prophylaxis following extrapleural pneumonectomy in patients with malignant pleural mesothelioma? |
| Q47340294 | When can we stop anticoagulation in patients with cancer-associated thrombosis? |
| Q50198318 | When to Screen Ischaemic Stroke Patients for Cancer |
| Q53321530 | [Arterial and venous thrombosis in lung cancer] |
| Q53256807 | [Diagnosis and management of acute pulmonary embolism. ESC guidelines 2014]. |
| Q82993880 | [Follow-up of pulmonary thromboembolism] |
| Q85334810 | [New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? No] |
| Q80938075 | [Treatment of deep vein thrombosis. When to use which substance?] |
| Q81512866 | [Treatment of venous thromboembolic disease] |